AI Can Summarize Research, But It Can’t Tell You What Experts Actually Think
A few years ago, a first look at a disease area meant a week of searching, reading and copying numbers into a spreadsheet, then hoping you hadn’t missed the one paper that mattered. Today you can type ...
Five Commercialization Mistakes Biotech Companies Make Before Launch (And a Checklist to Avoid Them)
Getting a drug approved is brutal. According to Tufts CSDD, only about 12% of drug candidates that enter clinical trials are ultimately approved, and CSDD's analysis put the full lifecycle cost of bri ...
Why Promising Drugs Struggle After FDA Approval: Understanding the Barriers to Market Success
For most drug developers, FDA approval feels like the finish line. Then launch day arrives and the real test begins.FDA approval confirms that a drug has met the applicable regulatory requirements for ...
Analog Selection in Pharma Forecasting: Getting It Right and Getting It Wrong
Every pharma forecast eventually leans on a comparison. Somewhere in the model there is a line that says, in effect, “our product will behave roughly like that one.” That product is the analog, and th ...
Which TPP Attributes Actually Matter? A Sensitivity-Driven Approach to Optimization
A Target Product Profile usually arrives as a table: indication, line of therapy, efficacy target, safety expectations, dosing, route of administration, positioning. Every row looks equally reasonable ...
The Evolution of PD-1/PD-L1: From Immune Checkpoint Breakthrough to What Comes After Keytruda
The protein was named for the wrong job. In 1992, Tasuku Honjo's group at Kyoto University was hunting for genes tied to cell death in T cells and cloned a new one. They called it programmed death-1, ...
Gorlin Syndrome Treatment Burden Problem: What the Patidegib Readout Could Change
Patients with severe Gorlin syndrome can face repeated surgeries year after year, many of them on the face. Each one can leave a scar, and a face only has so much tissue to spare.Most people meet basa ...
Treatment Pathway Mapping: Uncovering Hidden Unmet Need in Real-World Care
Background: A mid-size pharmaceutical company was preparing to advance a late-stage asset in a chronic, specialist-led disease area. Epidemiological modeling pointed to a sizable addressable populati ...
Forecasting Rare Disease Markets: Why Small Patient Populations Demand a More Rigorous Model
Rare disease markets have an odd commercial paradox built into them: the patient population is tiny, but the market opportunity can still be substantial. That's what makes forecasting them fundamental ...
What’s Driving R&D in Triple-Negative Breast Cancer
For years, chemotherapy was the backbone of triple-negative breast cancer (TNBC) treatment because the disease lacked the molecular targets that transformed treatment in other breast cancer subtypes. ...